HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

lignoceric acid (tetracosanoic acid)

RN given refers to parent cpd; structure
Also Known As:
tetracosanoic acid; N-tetracosanoic acid; lignoceric acid, potassium salt; lignoceric acid, silver (1+) salt; lignoceric acid, sodium salt; potassium tetracosanoate; tetracosanoic acid, potassium salt (1:1)
Networked: 51 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Lizard, Gérard: 3 articles (10/2018 - 01/2015)
2. Moreau, Thibault: 3 articles (10/2018 - 01/2015)
3. Nury, Thomas: 3 articles (10/2018 - 01/2015)
4. Bezine, Maryem: 2 articles (10/2018 - 10/2017)
5. Debbabi, Meryam: 2 articles (10/2018 - 10/2017)
6. Samadi, Mohammad: 2 articles (10/2018 - 10/2017)
7. Vejux, Anne: 2 articles (10/2018 - 10/2017)
8. Zarrouk, Amira: 2 articles (10/2018 - 01/2015)
9. de Sèze, Jérôme: 2 articles (10/2018 - 10/2017)
10. Deon, Marion: 2 articles (11/2007 - 09/2006)

Related Diseases

1. Adrenoleukodystrophy (Adrenoleukodystrophy, X-Linked)
2. Type 2 Diabetes Mellitus (MODY)
01/01/2014 - "Lignoceric acid is significantly associated with lower type 2 diabetes risk (ORβ€Š=β€Š0.95, 95% CI: 0.92-0.99, Pβ€Š=β€Š0.01). "
01/01/2020 - "Very-long-chain SFAs (VLCSFAs), such as arachidic acid (20:0), behenic acid (22:0), and lignoceric acid (24:0), have demonstrated inverse associations with cardiometabolic conditions, although more evidence is needed to characterize their relation with risk of type 2 diabetes (T2D). "
11/01/2023 - "A unique group of circulating very-long-chain saturated fatty acids (VLCSFAs), including arachidic acid (20:0), behenic acid (22:0), and lignoceric acid (24:0), have been associated with a lower risk of type 2 diabetes, although associations with early metabolic risk phenotypes preceding type 2 diabetes have received limited study. "
01/01/2022 - "In contrast to other saturated fatty acids, very long-chain saturated fatty acids (VLSFAs) have received limited attention The purpose of this review is to summarize the associations of VLSFAs, including arachidic acid, behenic acid, and lignoceric acid, with cardiovascular disease outcomes and type 2 diabetes; to discuss the findings implications; and to call for future studies of the VLSFAs. "
10/01/2014 - "By contrast, measured odd-chain SFAs (15:0 [pentadecanoic acid] and 17:0 [heptadecanoic acid]) were inversely associated with incident type 2 diabetes (HR [95% CI] per 1 SD difference: 0·79 [0·73-0·85] for pentadecanoic acid and 0·67 [0·63-0·71] for heptadecanoic acid), as were measured longer-chain SFAs (20:0 [arachidic acid], 22:0 [behenic acid], 23:0 [tricosanoic acid], and 24:0 [lignoceric acid]), with HRs ranging from 0·72 to 0·81 (95% CIs ranging between 0·61 and 0·92). "
3. Cardiovascular Diseases (Cardiovascular Disease)
4. Cognitive Dysfunction
5. Atherosclerosis

Related Drugs and Biologics

1. Fatty Acids (Saturated Fatty Acids)
2. long-chain-fatty-acid-CoA ligase
3. Ligases (Synthetase)
4. Enzymes
5. Acyl Coenzyme A (Acyl CoA)
6. Clofibrate
7. Hypolipidemic Agents (Antihyperlipidemics)
8. behenic acid (docosanoic acid)
9. arachidic acid
10. Phospholipids (Phosphatides)